Webinar: A clinical view on PITX2 DNA methylation in high-risk breast cancer

A webinar program for oncologists and pathologists

Thursday, Feb. 22, 2018 at 1:00 p.m. CET

Anthracycline-based chemotherapy is the recommended standard-of-care for certain high-risk breast cancer patients including lymph node-positive, estrogen receptor-positive and HER2-negative high-risk breast cancer patients. However, not all patients benefit equally from this chemotherapy. Learn more about a novel, validated marker that may help in selecting the most appropriate chemotherapy regimen for certain high-risk breast cancer patients.

Join Dr. Olaf Wilhelm for a dynamic discussion regarding PITX2 DNA methylation, a biomarker which may help improve therapy decision-making and support physicians in giving patient advice.


Prof. Dr. Olaf G. Wilhelm, MD, Founder and Chief Executive Officer of Therawis Pharma GmbH, Munich

Event Details

Date: Thurs. Feb 22, 2018

Place: From your desktop

Time: 1:00 p.m. CET

Duration: 1 hour

Cost: Free




Kathryn Collinet

Kathryn Collinet, PhD, is a Technical and Marketing Writer for Personalized Healthcare and Oncology at QIAGEN. She trained as a molecular biologist at the University of Barcelona and the Institute for Research in Biomedicine, where she studied DNA and protein modifications and their influence on chromatin conformation and gene expression. Since 2011 Kathryn has been working in marketing communications for the scientific information and molecular diagnostics industries. Kathryn has a passion for delivering knowledge and insights about molecular and clinical technologies, and their power to impact research and healthcare.

Your email address will not be published. Required fields are marked *